A 65-year-old man with a nearly obstructing sigmoid colon cancer underwent cardiac catheterization 4 months ago and was receiving clopidogrel for his coronary stent (last dose on the day prior to my evaluation). Therefore, his circulating platelets had undergone irreversible inhibition, causing altered function. An emergent/urgent operation may be associated with increased bleeding that could be managed with either platelet or red blood cell transfusion; cessation of clopidogrel for 7 days before the procedure would be anticipated to allow replacement of the circulating platelet volume with functional platelets but perhaps put his coronary stent at risk for thrombosis. While this latter event may be catastrophic, the per-day risk is quite minimal; in the placebo arm of the PCI-CURE (Percutaneous Coronary Intervention–Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial1 of clopidogrel therapy in patients undergoing percutaneous coronary intervention with stent placement, 7.2% of the patients experienced myocardial infarction, urgent revascularization, or cardiovascular death during a year of follow-up. The question remains whether the bleeding that occurs in patients undergoing abdominal surgery during active antiplatelet therapy is manageable or whether it is associated with life-threatening complications. Chernoguz et al retrospectively reviewed the medical records of 104 patients who underwent a variety of abdominal operations and evaluated the outcomes stratified by the timing of clopidogrel cessation. The finding of an increased rate of postoperative bleeding requiring red blood cell transfusion in patients whose clopidogrel was withdrawn less than 7 days prior to surgery compared with those in whom it was stopped 7 or more days prior to surgery is not surprising and is consistent with many other studies. However, when controlling for other factors associated with operative morbidity or mortality (eg, American Society of Anesthesiologists classification, urgency of procedure), there was not a significant increase in major morbidity or overall mortality.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.